The change in lifestyle and irregular eating habits of people is creating various health disorders, especially of the kidney and heart. The rise in the number of kidney problems around the world is helping the global Hyperphosphatemia therapeutics market to grow remarkably, says Fortune Business Insights in their recent study. The study is titled,” Hyperphosphatemia Therapeutics Market Size, Share and Global Trend By Product (Calcium-based phosphate binders, Aluminium-based phosphate binders, Magnesium-based phosphate binders, Iron-based phosphate binders), Dosage From (Tablets, Syrups, Capsules), Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) and Geography Forecast till 2026.”
Request Sample Copy at
Top Players Overview:
Some of the leading companies that are operating in the Global Hyperphosphatemia Therapeutics Market are
- Johnson & Johnson Services, Inc.
- Keryx Biopharmaceuticals, Inc.
- Astellas Pharma Inc.
- Ardelyx, BioLink Life Sciences, Inc.
- Lupin Pharmaceuticals, Inc.
- Fresenius Medical Care AG & Co. KGa
- Vifor Pharma Management Ltd.
- other players.
Rising Cases of Chronic Kidney Disorders and Renal Problems Boosting Market
At present, the introduction and utilization of new drugs that are developed for treating chronic diseases is helping the market gain quick momentum. This is because of the adverse effects of such drugs that are boosting the global market for Hyperphosphatemia therapeutics during the forecast duration.
Hyperphosphatemia is caused as a result of excessive phosphate level in the blood. Phosphate being an important component for genetic coding, cell and bone arrangement, and energy metabolism is essential form of phosphorous for the body. People with kidney disorders and especially end-stage kidney disease commonly face problems such as hyperphosphatemia. Thus, the rising incidences of kidney problems are anticipated to boost the global market for hyperphosphatemia.
Other factors responsible for the rapid expansion of the global hyperphosphatemia market include the rising incidences of diabetic ketoacidosis, high vitamin D levels, low parathyroid hormone levels, and uncontrolled diabetics. The geriatric population is more prone to fall prey to such health disorders, which is further expected to help drive the market during the forecast period.
On the flipside, the lack of awareness about hyperphosphatemia and its benefits may restrict the market from growing in future. Additionally, the high cost of treatment and medication related to the hyperphosphatemia therapeutics may also hinder its growth in future. This, coupled with non-adherence to treatment regimens may also hamper its growth during the forecast period.
Nevertheless, the increasing number of patients undergoing dialysis may bring lucrative growth opportunities for the market in the long run. This is because patients suffering from renal failure or in end stage of kidney disease require phosphorous in their medication.
Asia Pacific to Witness Faster Growth on Account of Better Reimbursement Policies
Fortune Business Insights foresees the global hyperphosphatemia therapeutics market to be dominated by North America. This is owing to the rising incidences of kidney diseases in the region. Additionally, the presence of well-developed health infrastructures is further propelling demand for new and advanced treatment for hyperphosphatemia in the region, thus, boosting market growth.
Furthermore, the market in Asia Pacific is expected to show faster growth in the forecast period, owing to the rising disposable income of people in the region which helps them to opt for better treatment options. Again, reimbursement policies issued by governments in developing nations of China and India are also helping people in the region opt for hyperphosphatemia therapeutics. Again, the increasing number of healthcare organizations and betterment of facilities in such organizations is also expected to help surge the market in future.
Some of the companies operating in the global Hyperphosphatemia therapeutics market are Fresenius Medical Care AG & Co. KGaA, Astellas Pharma Inc., Vifor Pharma Management Ltd., Keryx Biopharmaceuticals, Inc., Ardelyx, Lupin Pharmaceuticals, Inc., BioLink Life Sciences, Inc., and Johnson & Johnson Services, Inc.
Browse Complete Report Details at